Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

AbbVie Inc., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Price to earnings (P/E) 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82
Price to operating profit (P/OP) 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82
Price to sales (P/S) 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22
Price to book value (P/BV) 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc. P/E ratio increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc. P/OP ratio increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc. P/S ratio decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. AbbVie Inc. P/BV ratio decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Price to Earnings (P/E)

AbbVie Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 1,766,473,359 1,765,537,421 1,765,046,680 1,764,289,680 1,769,399,971 1,768,480,508 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177
Selected Financial Data (US$)
Net earnings (loss) attributable to AbbVie Inc. (in millions) 822 1,778 2,024 239 2,473 3,949 924 4,490 4,044 3,179 766 3,553 36 2,308 (738) 3,010 2,801 1,884 741 2,456
Earnings per share (EPS)2 2.75 3.69 4.92 4.30 6.69 7.58 7.15 7.06 6.53 4.26 3.77 2.92 2.61 4.18 3.94 5.71 5.33 0.00 0.00 0.00
Share price1, 3 175.75 141.20 150.33 148.03 151.31 145.28 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71
Valuation Ratio
P/E ratio4 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64 22.07 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82
Benchmarks
P/E Ratio, Competitors5
Amgen Inc. 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23 21.05 21.91 22.56 19.20 18.82 17.25 19.97 17.70 17.07
Bristol-Myers Squibb Co. 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64 20.92 144.77 41.99
Eli Lilly & Co. 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29 40.66 40.07 40.34 28.77 31.95 22.54 25.59 26.56 16.19
Gilead Sciences Inc. 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25 12.36 11.44 16.83 277.25 641.48 59.19 19.58 16.45
Johnson & Johnson 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95 20.93 23.98 25.51 28.35 28.92 22.51 25.68 23.06 25.99
Merck & Co. Inc. 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70 14.78 28.65 34.23 28.00 26.72 17.67 19.70 19.18 20.60
Pfizer Inc. 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11 11.76 14.03 20.05 20.15 19.62 25.36 14.99 13.04 11.63
Regeneron Pharmaceuticals Inc. 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15 8.37 9.96 10.38 13.27 15.09 19.91 22.27 28.35 19.86
Thermo Fisher Scientific Inc. 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15 27.35 29.43 24.63 23.23 27.89 38.43 44.19 35.50 33.36
Vertex Pharmaceuticals Inc. 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50 26.55 22.09 26.26 20.45 20.18 20.14 34.05 43.74 52.90

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2023 Calculation
EPS = (Net earnings (loss) attributable to AbbVie Inc.Q4 2023 + Net earnings (loss) attributable to AbbVie Inc.Q3 2023 + Net earnings (loss) attributable to AbbVie Inc.Q2 2023 + Net earnings (loss) attributable to AbbVie Inc.Q1 2023) ÷ No. shares of common stock outstanding
= (822,000,000 + 1,778,000,000 + 2,024,000,000 + 239,000,000) ÷ 1,766,473,359 = 2.75

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q4 2023 Calculation
P/E ratio = Share price ÷ EPS
= 175.75 ÷ 2.75 = 63.84

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc. P/E ratio increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Price to Operating Profit (P/OP)

AbbVie Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 1,766,473,359 1,765,537,421 1,765,046,680 1,764,289,680 1,769,399,971 1,768,480,508 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177
Selected Financial Data (US$)
Operating earnings (in millions) 3,195 2,281 4,513 2,768 5,502 4,603 3,295 4,717 5,074 4,306 4,441 4,103 3,753 3,255 752 3,603 3,956 2,617 3,400 3,010
Operating profit per share2 7.22 8.53 9.85 9.16 10.24 10.00 9.84 10.49 10.13 9.39 8.80 6.72 6.43 6.55 6.19 9.19 8.78 0.00 0.00 0.00
Share price1, 3 175.75 141.20 150.33 148.03 151.31 145.28 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71
Valuation Ratio
P/OP ratio4 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57 14.21 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82
Benchmarks
P/OP Ratio, Competitors5
Amgen Inc. 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88 16.24 16.73 17.48 15.26 14.96 13.82 15.84 14.22 13.84
Bristol-Myers Squibb Co. 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32 19.84 39.45 33.97 27.33 24.42
Eli Lilly & Co. 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49 35.70 37.21 42.01 31.17 32.66 22.98 25.58 24.82 27.08
Gilead Sciences Inc. 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78 7.76 7.27 8.88 18.31 19.38 29.86 21.83 20.66
Johnson & Johnson 17.78 14.60 17.63 17.65 17.62 19.64 20.45 21.06 18.68 18.99 20.14 21.12 21.84 19.46 19.66 18.67 19.83
Merck & Co. Inc. 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29 15.39 30.71 38.03 30.14 23.89 16.00 17.23 15.88 17.47
Pfizer Inc. 700.76 18.89 9.37 6.78 6.80 7.82 9.11 11.49 13.30 16.37 19.83 22.85 23.12 22.27 22.17 17.42 14.36
Regeneron Pharmaceuticals Inc. 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98 7.55 9.32 9.65 13.32 14.82 20.36 23.98 26.60 19.01
Thermo Fisher Scientific Inc. 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84 21.07 23.87 19.77 18.53 22.81 31.49 36.59 28.44 26.84
Vertex Pharmaceuticals Inc. 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13 22.35 18.14 23.06 18.68 19.16 20.35 33.91 40.27 51.98

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2023 Calculation
Operating profit per share = (Operating earningsQ4 2023 + Operating earningsQ3 2023 + Operating earningsQ2 2023 + Operating earningsQ1 2023) ÷ No. shares of common stock outstanding
= (3,195,000,000 + 2,281,000,000 + 4,513,000,000 + 2,768,000,000) ÷ 1,766,473,359 = 7.22

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q4 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 175.75 ÷ 7.22 = 24.34

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc. P/OP ratio increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Price to Sales (P/S)

AbbVie Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 1,766,473,359 1,765,537,421 1,765,046,680 1,764,289,680 1,769,399,971 1,768,480,508 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177
Selected Financial Data (US$)
Net revenues (in millions) 14,301 13,927 13,865 12,225 15,121 14,812 14,583 13,538 14,886 14,342 13,959 13,010 13,858 12,902 10,425 8,619 8,704 8,479 8,255 7,828
Sales per share2 30.75 31.23 31.74 32.16 32.81 32.69 32.44 32.10 31.77 31.21 30.40 28.42 25.94 23.02 20.53 23.06 22.49 0.00 0.00 0.00
Share price1, 3 175.75 141.20 150.33 148.03 151.31 145.28 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71
Valuation Ratio
P/S ratio4 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76 4.53 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22
Benchmarks
P/S Ratio, Competitors5
Amgen Inc. 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21 5.10 5.04 5.37 5.68 5.64 5.33 6.30 5.96 6.03
Bristol-Myers Squibb Co. 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41 3.16 2.85 3.44 3.28 3.16 3.66 3.97 4.45 5.52
Eli Lilly & Co. 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47 8.01 8.62 9.16 6.88 8.06 5.41 6.26 6.36 6.03
Gilead Sciences Inc. 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86 2.85 3.11 3.30 3.31 3.24 3.29 3.95 4.34 4.00
Johnson & Johnson 4.43 3.68 4.45 4.42 4.34 4.69 4.80 5.00 4.66 4.69 5.08 5.09 5.15 4.73 4.84 4.78 4.79
Merck & Co. Inc. 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12 3.96 4.32 4.05 4.23 3.93 4.30 4.38 4.05 4.33
Pfizer Inc. 2.66 2.54 2.60 2.33 2.37 2.63 2.77 3.00 3.18 4.04 4.78 4.84 4.50 4.71 4.69 4.21 3.66
Regeneron Pharmaceuticals Inc. 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40 4.20 5.14 5.20 5.78 6.24 7.62 8.31 8.10 5.34
Thermo Fisher Scientific Inc. 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20 5.39 6.45 5.54 5.13 5.52 6.58 6.24 5.08 4.83
Vertex Pharmaceuticals Inc. 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17 8.21 6.74 7.82 8.81 8.82 9.04 13.11 13.71 14.95

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2023 Calculation
Sales per share = (Net revenuesQ4 2023 + Net revenuesQ3 2023 + Net revenuesQ2 2023 + Net revenuesQ1 2023) ÷ No. shares of common stock outstanding
= (14,301,000,000 + 13,927,000,000 + 13,865,000,000 + 12,225,000,000) ÷ 1,766,473,359 = 30.75

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q4 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 175.75 ÷ 30.75 = 5.72

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc. P/S ratio decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Price to Book Value (P/BV)

AbbVie Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 1,766,473,359 1,765,537,421 1,765,046,680 1,764,289,680 1,769,399,971 1,768,480,508 1,768,096,495 1,767,110,083 1,768,753,829 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177
Selected Financial Data (US$)
Stockholders’ equity (deficit) (in millions) 10,360 12,094 12,866 13,274 17,254 15,994 14,653 16,283 15,408 13,550 12,569 13,710 13,076 15,270 14,708 (7,415) (8,172) (8,226) (8,566) (7,826)
Book value per share (BVPS)2 5.86 6.85 7.29 7.52 9.75 9.04 8.29 9.21 8.71 7.66 7.11 7.76 7.40 8.65 8.33 -5.02 -5.52 -5.56 -5.79 -5.29
Share price1, 3 175.75 141.20 150.33 148.03 151.31 145.28 138.92 152.83 144.03 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71
Valuation Ratio
P/BV ratio4 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59 16.53 15.20 16.23 14.91 14.18 10.93 11.31
Benchmarks
P/BV Ratio, Competitors5
Amgen Inc. 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87 18.51 14.95 15.72 14.57 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92
Bristol-Myers Squibb Co. 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07 4.07 3.48 4.15 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91
Eli Lilly & Co. 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75 25.28 30.85 38.00 25.41 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37
Gilead Sciences Inc. 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91 3.65 3.94 4.41 4.40 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83
Johnson & Johnson 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36 5.90 6.10 6.51 6.51 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39
Merck & Co. Inc. 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44 5.05 5.76 5.73 7.30 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31
Pfizer Inc. 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37 3.35 3.69 3.78 3.27 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84
Regeneron Pharmaceuticals Inc. 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65 3.60 4.04 4.26 4.44 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74
Thermo Fisher Scientific Inc. 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23 5.18 6.51 5.75 5.25 5.15 5.89 5.48 4.56 4.16 4.15 3.83 4.02
Vertex Pharmaceuticals Inc. 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95 6.16 5.04 5.69 6.29 6.30 6.66 9.42 10.23 10.23 9.57 9.09 9.36

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2023 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= 10,360,000,000 ÷ 1,766,473,359 = 5.86

3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.

4 Q4 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 175.75 ÷ 5.86 = 29.97

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. AbbVie Inc. P/BV ratio decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.